About Vertex Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.vrtx.com/
Frequently Asked Questions
What is the 52-week range for VRTX?
The 52-week high is $560.25 and the 52-week low is $392.5.
What is the P/E ratio for VRTX?
The Price to Earnings (P/E) ratio is 30.08.
What is the dividend yield for VRTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 23.31%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 35.00%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.16.
Analyst Recommendation Trends
Wall Street analyst consensus for VRTX over the last few months:
Latest VRTX News
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select biotechnology stocks with more reasonable finances can draw interest. This article breaks down three biotech stocks from a curated screener that aims to balance high upside with some measure of financial discipline. The stocks covered below are just a small...
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.
Vortex Energy Completes Acquisition of the Meadows Project in Saskatchewan
VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) ("Vortex" or the "Company") is pleased to announce that, further to its news release dated September 17, 2026, it has completed the acquisition (the “Acquisition”) of the Purchased Assets (as defined below) comprising the Meadows Project located in west-central Saskatchewan near the Alberta border (the "Meadows Project"). The Meadows Project is represented by Saskatchewan Subsur
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.
The Top HealthTech Questions Landing On Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 19.81%. Currently, Vertex Pharmaceuticals has a market
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
This biotech player is firing on all cylinders.
Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade
Vertex Pharmaceuticals commands a dominant, highly profitable cystic fibrosis franchise. Find out why VRTX stock is downgraded to a hold.
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]
Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for Vertex and Okta, while cutting targets for McDonald’s, AutoZone, Vaxcyte and Camping World.
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.
2 Healthcare Stocks to Target This Week and 1 We Avoid
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 46.9% over the past six months, topping the S&P 500 by 25.5 percentage points.
2 Healthcare Stocks That Just Delivered Great News for Investors
And there could be more positive developments ahead.
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals. Recent trading has been choppy for Maze Therapeutics, with a 1-day share price return that declined 6.69% following a 7-day share price return up 11.82%. The year-to-date share price return is down...
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
Lilly’s latest China drug deal; Immunovant’s setback in lupus
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. With the stock near recent highs after a series of clinical and commercial updates, the open question is whether the current market price lines up with the cash the business is expected to generate over time. Over the past 5 years, Vertex Pharmaceuticals has...
Vertex Posts Positive Phase II Data on Kidney Disease Drug
VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target.
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race
Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy Market Autologous Hematopoietic Stem Cell Gene Therapy Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Autologous Hematopoietic Stem Cell Gene Therapy Mar
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.
SBIO: Big Pharma Needs What This Fund Owns
The ALPS Medical Breakthroughs ETF is a Buy, as its pullback offers a better entry into late-stage biotech. Click for more on the SBIO ETF.
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug
Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.
Chronic Kidney Disease (CKD) Market Gains Momentum as Pipeline Innovation and Clinical Trials Reshape the Competitive Landscape in 2026
CKD drug development is shifting toward disease-modifying and cardiorenal therapies, creating opportunities in early detection, high-risk screening, combinations and licensingDublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Chronic Kidney Disease - Competitive Landscape and Clinical Trial Analysis, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of more than 90 companies and over 100 marketed and investigational drugs within the global chronic
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
BOSTON, September 22, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.
Vertex Pharmaceuticals Announces Results From Phase 2b AMPLIFIED Study Of Inaxaplin In People With Kidney Disease And Type-2 Diabetes; Treatment With Inaxaplin Led To Reduction In Urine Albumin To Creatinine Ratio Of -42.7% At Week 13 Compared To Baseline; Inaxaplin Was Generally Safe And Well Tolerated In Both Cohorts
Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.In this study, inaxaplin was evaluated as a 45 mg once-daily
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.
2 Reasons to Like VRTX (and 1 Not So Much)
Vertex Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.9% to $514.18 per share while the index has gained 14%.
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?
This company has had plenty of setbacks in recent years, but it generally bounces back.
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.
Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan
VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Global Strategic Minerals Corp. (the “Vendor”), pursuant to which the Company will acquire (the “Transaction”) the Purchased Assets (as defined below) comprising the Meadows Project (the “Project”) located in west-central Saskatchewan nea
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.
Will Vertex’s (VRTX) New CFO Elevation and Digital Focus Reframe Its Capital Allocation Narrative?
In August 2026, Vertex Pharmaceuticals announced that Senior Vice President of Finance Jonathan Poole will become Executive Vice President and Chief Financial Officer on January 1, 2027, while Charles F. Wagner Jr. remains Executive Vice President and Chief Operating Officer. This internal promotion, paired with Vertex’s increased external visibility through forums such as the Boston C-Level Technology Leadership Summit, highlights how the company is elevating both its financial leadership...
Vertex Pharmaceuticals (VRTX), Why Is It Getting Fresh Attention Now?
Vertex Pharmaceuticals (VRTX) has been in focus after presenting at the 18th Annual Boston C-Level Technology Leadership Summit on September 10, where its Chief Digital and Information Officer outlined the group’s technology priorities. Recent trading has been choppy for Vertex Pharmaceuticals, with the share price falling 4.9% over the past week but still showing a 14.6% 90 day share price return and a 32.1% 1 year total shareholder return. This points to momentum that has built over a...
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened?
Vera stock reversed course Tuesday despite positive results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex.
Undercovered Dozen: Ares Capital, Grab, Lenovo, Rigetti And More
Discover Seeking Alphaâs Undercovered Dozenâ12 under-the-radar stocks for fresh investment ideas.
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
BOSTON, September 15, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in January 2025, JOURNAVX marked the first new class of pain medicine in over 20 years — since then JOURNAVX has been prescribed to ove
1 Unpopular Stock That Should Get More Attention and 2 We Brush Off
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead
Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s priorities, CEO and President Reshma Kewalramani said at Morgan Stanley’s 24th Annual Healthcare Conferen
Vortex Energy Engages Lonquist to Manage Ground Gravity Survey at the Robinsons River Salt Project
Lonquist to lead survey planning and data acquisition, building on recent technical work at Robinsons RiverVANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has engaged Lonquist Field Service (Canada), ULC (“Lonquist”) to manage a targeted ground gravity survey at its 100%-owned Robinsons River Salt Project (the “Project”) in Newfoundland and Labrador. The engagement a
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis
Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance. Susie Lisa, the company’s head of investor relations, s
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis an
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup […]
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
Both companies are approaching milestones that could light a fire under their stocks.
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 2:10 PM EDTCompany...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 4:30 PM EDTCompany ParticipantsConference Call...
Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution
Vertex Pharmaceuticals (VRTX) rated Hold: CF growth is solid but valuation, margin pressure and new-launch execution risks cap upside.
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
The company has tremendous prospects.
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.
Why CRISPR Therapeutics Stock Rocked the Market Last Month
The company had fallen out of investor favor; its recovery was impressive.
3 Market-Beating Stocks for Long-Term Investors
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Where Will CRISPR Therapeutics Stock Be in 5 Years?
CRISPR's expanding pipeline could unlock significantly more value by 2031.
Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit
FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Technology Leadership Summit, qualified technology executives are encouraged to secure their seats now while limited seating remains available. The September 10 summit at The Harvard Club of Boston will bring together CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology leaders to discuss AI governance, Agen
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?
CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case
CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP is rated a Buy.
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
They could both outperform the market over the medium term, but one appears to have a clear edge.
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals has a market
Vortex Energy Announces Plans for Ground Gravity Survey at the Robinsons River Salt Project
Next Phase of Geophysical Work Advances Priority Targets Following August Technical StudyVANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce plans to undertake a targeted ground gravity survey at its 100%-owned Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoundland and Labrador. The survey has been selected as the Co
The Market May Be Telling Us We're Entering A Capital Formation Cycle
My clustering stock screener is giving us a much more interesting macro signal than simply energy stocks are strong. The portfolio is not simply long commodities. It's long capital intensity
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-08 | van Grunsven Jasper | +8,682 | - | - |
| 2026-08-28 | Ambrose Kristen | +5,000 | - | - |
| 2026-08-27 | SACHS BRUCE I | -6,000 | - | - |
| 2026-07-21 | Tatsis Ourania | +8,251 | - | - |
| 2026-07-21 | Sachdev Amit | +8,251 | - | - |
| 2026-07-15 | Garber Alan M | +32 | $475.28 | $15,209 |
| 2026-07-15 | SACHS BRUCE I | +100 | $475.28 | $47,528 |
| 2026-07-02 | McKechnie Duncan | -1,541 | $519 | $799,779 |
| 2026-07-02 | Tatsis Ourania | -1,500 | $524.99 | $787,485 |
| 2026-07-01 | Liu Joy | -828 | $502.71 | $416,244 |
| 2026-06-18 | Bozic Carmen | -1,020 | $462.17 | $471,413 |
| 2026-06-05 | Bozic Carmen | -1,745 | $450 | $785,250 |
| 2026-06-01 | Liu Joy | -828 | $439.91 | $364,245 |
| 2026-05-29 | Bozic Carmen | -1,974 | $450 | $888,300 |
| 2026-05-15 | Bunnage Mark E. | -33 | $453.45 | $14,964 |
| 2026-05-15 | Bozic Carmen | -1,354 | $453.45 | $613,971 |
| 2026-05-12 | Bozic Carmen | -6,988 | $450 | $3,144,600 |
| 2026-05-04 | Bhatia Sangeeta N. | -318 | $423.73 | $134,746 |
| 2026-05-01 | Bhatia Sangeeta N. | +943 | - | - |
| 2026-05-01 | Liu Joy | -1,104 | $425.02 | $469,222 |
| 2026-05-01 | Thornberry Nancy | +398 | - | - |
| 2026-05-01 | Thornberry Nancy | +1,433 | - | - |
| 2026-05-01 | Thornberry Nancy | -398 | - | - |
| 2026-05-01 | Thornberry Nancy | +472 | - | - |
| 2026-05-01 | Schneider Jennifer | +796 | - | - |
| 2026-05-01 | Schneider Jennifer | +1,433 | - | - |
| 2026-05-01 | Schneider Jennifer | -796 | - | - |
| 2026-05-01 | Schneider Jennifer | +472 | - | - |
| 2026-05-01 | MCKENZIE DIANA | +796 | - | - |
| 2026-05-01 | MCKENZIE DIANA | -796 | - | - |
| 2026-05-01 | MCKENZIE DIANA | +943 | - | - |
| 2026-05-01 | Upadhyay Suketu | +796 | - | - |
| 2026-05-01 | Upadhyay Suketu | +2,866 | - | - |
| 2026-05-01 | Upadhyay Suketu | -796 | - | - |
| 2026-05-01 | Lagarde Michel | +2,866 | - | - |
| 2026-05-01 | Garber Alan M | +1,433 | - | - |
| 2026-05-01 | Garber Alan M | +472 | - | - |
| 2026-05-01 | CARNEY LLOYD | +2,866 | - | - |
| 2026-05-01 | SACHS BRUCE I | +2,866 | - | - |
| 2026-04-15 | Upadhyay Suketu | +81 | $442.5 | $35,843 |
| 2026-04-15 | Garber Alan M | +34 | $442.5 | $15,045 |
| 2026-04-15 | SACHS BRUCE I | +107 | $442.5 | $47,348 |
| 2026-04-01 | Liu Joy | -978 | $449.17 | $439,288 |
| 2026-03-27 | Bozic Carmen | -2,329 | $450.95 | $1,050,263 |
| 2026-03-13 | Bozic Carmen | -2,329 | $481.79 | $1,122,089 |
| 2026-03-11 | McKechnie Duncan | -2,633 | $498.42 | $1,312,340 |
| 2026-03-04 | McKechnie Duncan | -2,437 | $475.3 | $1,158,306 |
| 2026-03-02 | Liu Joy | -892 | $495.96 | $442,396 |
| 2026-02-27 | Kewalramani Reshma | -1,725 | $496.95 | $857,239 |
| 2026-02-27 | Kewalramani Reshma | -5,995 | $496.16 | $2,974,479 |
| 2026-02-27 | Kewalramani Reshma | -15,580 | $495.38 | $7,718,020 |
| 2026-02-27 | Kewalramani Reshma | -3,498 | $494.33 | $1,729,166 |
| 2026-02-27 | Kewalramani Reshma | -2,520 | $493.29 | $1,243,091 |
| 2026-02-27 | Kewalramani Reshma | -949 | $491.3 | $466,244 |
| 2026-02-27 | Kewalramani Reshma | -2,725 | $490.54 | $1,336,722 |
| 2026-02-27 | Kewalramani Reshma | -460 | $489.32 | $225,087 |
| 2026-02-27 | Kewalramani Reshma | -3,278 | $488.27 | $1,600,549 |
| 2026-02-27 | Kewalramani Reshma | -2,510 | $487.13 | $1,222,696 |
| 2026-02-27 | Kewalramani Reshma | -240 | $482.84 | $115,882 |
| 2026-02-27 | Kewalramani Reshma | -120 | $481.5 | $57,780 |
| 2026-02-27 | Kewalramani Reshma | -400 | $479.75 | $191,900 |
| 2026-02-27 | Bozic Carmen | -2,329 | $480.31 | $1,118,642 |
| 2026-02-26 | Ambrose Kristen | -357 | $483.36 | $172,560 |
| 2026-02-25 | Bunnage Mark E. | -620 | $486.35 | $301,537 |
| 2026-02-25 | McKechnie Duncan | -2,410 | $489 | $1,178,490 |
| 2026-02-25 | McKechnie Duncan | -2,500 | $486.35 | $1,215,875 |
| 2026-02-25 | Atkinson Edward Morrow III | -668 | $486.35 | $324,882 |
| 2026-02-25 | Ambrose Kristen | -223 | $486.35 | $108,456 |
| 2026-02-25 | Tatsis Ourania | -260 | $486.35 | $126,451 |
| 2026-02-25 | Biller Jonathan | -945 | $486.35 | $459,601 |
| 2026-02-25 | Sachdev Amit | -1,846 | $486.35 | $897,802 |
| 2026-02-24 | Bunnage Mark E. | -582 | $485.11 | $282,334 |
| 2026-02-24 | McKechnie Duncan | -873 | $485.11 | $423,501 |
| 2026-02-24 | Atkinson Edward Morrow III | -1,627 | $485.11 | $789,274 |
| 2026-02-24 | Ambrose Kristen | -546 | $485.11 | $264,870 |
| 2026-02-24 | Bozic Carmen | -1,453 | $485.11 | $704,865 |
| 2026-02-24 | Tatsis Ourania | -1,627 | $485.11 | $789,274 |
| 2026-02-24 | Biller Jonathan | -1,144 | $485.11 | $554,966 |
| 2026-02-24 | Kewalramani Reshma | -4,981 | $485.11 | $2,416,333 |
| 2026-02-24 | Sachdev Amit | -1,518 | $485.11 | $736,397 |
| 2026-02-24 | LEIDEN JEFFREY M | -3,547 | $485.11 | $1,720,685 |
| 2026-02-24 | WAGNER CHARLES F JR | -1,744 | $485.11 | $846,032 |
| 2026-02-19 | Sachdev Amit | -25,026 | - | - |
| 2026-02-19 | Sachdev Amit | -23,479 | - | - |
| 2026-02-19 | Sachdev Amit | -4,237 | $471.43 | $1,997,449 |
| 2026-02-19 | Sachdev Amit | -11,712 | $470.54 | $5,510,964 |
| 2026-02-19 | Sachdev Amit | -7,241 | $469.61 | $3,400,446 |
| 2026-02-19 | Sachdev Amit | -19,662 | $468.57 | $9,213,023 |
| 2026-02-19 | Sachdev Amit | -10,263 | $467.75 | $4,800,518 |
| 2026-02-19 | Sachdev Amit | -1,848 | $465.8 | $860,798 |
| 2026-02-19 | Sachdev Amit | -2,730 | $465.05 | $1,269,587 |
| 2026-02-19 | Sachdev Amit | -920 | $463.91 | $426,797 |
| 2026-02-19 | Sachdev Amit | +25,026 | $187.53 | $4,693,126 |
| 2026-02-19 | Sachdev Amit | +23,479 | $155.57 | $3,652,628 |
| 2026-02-18 | Bunnage Mark E. | -1,182 | $473.68 | $559,890 |
| 2026-02-18 | Atkinson Edward Morrow III | -817 | $473.68 | $386,997 |
| 2026-02-18 | Ambrose Kristen | -638 | $473.68 | $302,208 |
| 2026-02-18 | Tatsis Ourania | -368 | $473.68 | $174,314 |
| 2026-02-18 | Biller Jonathan | -1,244 | $473.68 | $589,258 |
| 2026-02-18 | LEIDEN JEFFREY M | -2,964 | $483.75 | $1,433,835 |
| 2026-02-17 | Bunnage Mark E. | -2,437 | $489.46 | $1,192,814 |
| 2026-02-17 | Bunnage Mark E. | -1,110 | $483.75 | $536,963 |
| 2026-02-17 | Bunnage Mark E. | +2,584 | - | - |
| 2026-02-17 | McKechnie Duncan | -1,148 | $483.75 | $555,345 |
| 2026-02-17 | McKechnie Duncan | +4,962 | - | - |
| 2026-02-17 | Atkinson Edward Morrow III | -2,031 | $489.46 | $994,093 |
| 2026-02-17 | Atkinson Edward Morrow III | -1,530 | $483.75 | $740,138 |
| 2026-02-17 | Atkinson Edward Morrow III | +4,962 | - | - |
| 2026-02-17 | Ambrose Kristen | -1,557 | $489.46 | $762,089 |
| 2026-02-17 | Ambrose Kristen | -598 | $483.75 | $289,283 |
| 2026-02-17 | Ambrose Kristen | +1,809 | - | - |
| 2026-02-17 | Bozic Carmen | -1,912 | $483.75 | $924,930 |
| 2026-02-17 | Bozic Carmen | +5,375 | - | - |
| 2026-02-17 | Tatsis Ourania | -609 | $489.46 | $298,081 |
| 2026-02-17 | Tatsis Ourania | -2,294 | $483.75 | $1,109,723 |
| 2026-02-17 | Tatsis Ourania | +5,789 | - | - |
| 2026-02-17 | Biller Jonathan | -2,476 | $489.46 | $1,211,903 |
| 2026-02-17 | Biller Jonathan | -1,505 | $483.75 | $728,044 |
| 2026-02-17 | Biller Jonathan | +4,135 | - | - |
| 2026-02-17 | Kewalramani Reshma | -6,554 | $483.75 | $3,170,498 |
| 2026-02-17 | Kewalramani Reshma | +16,326 | - | - |
| 2026-02-17 | Sachdev Amit | -2,140 | $483.75 | $1,035,225 |
| 2026-02-17 | Sachdev Amit | +5,789 | - | - |
| 2026-02-17 | LEIDEN JEFFREY M | +8,269 | - | - |
| 2026-02-17 | WAGNER CHARLES F JR | -2,294 | $483.75 | $1,109,723 |
| 2026-02-17 | WAGNER CHARLES F JR | +7,365 | - | - |
| 2026-02-13 | Bunnage Mark E. | -2,283 | $487.76 | $1,113,556 |
| 2026-02-13 | McKechnie Duncan | -2,283 | $487.76 | $1,113,556 |
| 2026-02-13 | Atkinson Edward Morrow III | -1,903 | $487.76 | $928,207 |
| 2026-02-13 | Ambrose Kristen | -1,393 | $487.76 | $679,450 |
| 2026-02-13 | Bozic Carmen | -3,804 | $487.76 | $1,855,439 |
| 2026-02-13 | Tatsis Ourania | -1,500 | $499.99 | $749,985 |
| 2026-02-13 | Tatsis Ourania | -3,804 | $487.76 | $1,855,439 |
| 2026-02-13 | Biller Jonathan | -988 | $499 | $493,012 |
| 2026-02-13 | Biller Jonathan | -2,993 | $487.76 | $1,459,866 |
| 2026-02-13 | Kewalramani Reshma | -13,041 | $487.76 | $6,360,878 |
| 2026-02-13 | Bhatia Sangeeta N. | -266 | $500 | $133,000 |
| 2026-02-13 | Sachdev Amit | -3,548 | $487.76 | $1,730,572 |
| 2026-02-13 | WAGNER CHARLES F JR | -4,565 | $487.76 | $2,226,624 |
| 2026-02-11 | Bunnage Mark E. | -2,021 | $460.43 | $930,529 |
| 2026-02-11 | Atkinson Edward Morrow III | -1,751 | $460.43 | $806,213 |
| 2026-02-11 | Ambrose Kristen | -1,376 | $460.43 | $633,552 |
| 2026-02-11 | Tatsis Ourania | -466 | $460.43 | $214,560 |
| 2026-02-11 | Biller Jonathan | -1,925 | $460.43 | $886,328 |
| 2026-02-10 | Bunnage Mark E. | -1,127 | $468.41 | $527,898 |
| 2026-02-10 | McKechnie Duncan | -1,127 | $468.41 | $527,898 |
| 2026-02-10 | Atkinson Edward Morrow III | -872 | $468.41 | $408,454 |
| 2026-02-10 | Ambrose Kristen | -592 | $468.41 | $277,299 |
| 2026-02-10 | Bozic Carmen | -2,145 | $468.41 | $1,004,739 |
| 2026-02-10 | Tatsis Ourania | -2,140 | $468.41 | $1,002,397 |
| 2026-02-10 | Biller Jonathan | -1,630 | $468.41 | $763,508 |
| 2026-02-10 | Kewalramani Reshma | -8,297 | $468.41 | $3,886,398 |
| 2026-02-10 | Sachdev Amit | -2,057 | $468.41 | $963,519 |
| 2026-02-10 | WAGNER CHARLES F JR | -3,045 | $468.41 | $1,426,308 |
| 2026-01-22 | McKechnie Duncan | +2,080 | - | - |
| 2026-01-22 | McKechnie Duncan | +4,720 | - | - |
| 2026-01-22 | Atkinson Edward Morrow III | +3,883 | - | - |
| 2026-01-22 | Atkinson Edward Morrow III | +3,934 | - | - |
| 2026-01-22 | Ambrose Kristen | +1,300 | - | - |
| 2026-01-22 | Ambrose Kristen | +2,950 | - | - |
| 2026-01-22 | Bozic Carmen | +3,467 | - | - |
| 2026-01-22 | Bozic Carmen | +7,866 | - | - |
| 2026-01-22 | Tatsis Ourania | +3,883 | - | - |
| 2026-01-22 | Tatsis Ourania | +7,866 | - | - |
| 2026-01-22 | Biller Jonathan | +2,774 | - | - |
| 2026-01-22 | Biller Jonathan | +6,294 | - | - |
| 2026-01-22 | Kewalramani Reshma | +11,885 | - | - |
| 2026-01-22 | Kewalramani Reshma | +26,972 | - | - |
| 2026-01-22 | ALTSHULER DAVID | +3,328 | - | - |
| 2026-01-22 | ALTSHULER DAVID | +7,866 | - | - |
| 2026-01-22 | Sachdev Amit | +3,883 | - | - |
| 2026-01-22 | Sachdev Amit | +7,866 | - | - |
| 2026-01-22 | LEIDEN JEFFREY M | +9,012 | - | - |
| 2026-01-22 | WAGNER CHARLES F JR | +4,160 | - | - |
| 2026-01-22 | WAGNER CHARLES F JR | +9,440 | - | - |
| 2026-01-15 | Upadhyay Suketu | +80 | $443.56 | $35,485 |
| 2026-01-15 | SACHS BRUCE I | +107 | $443.56 | $47,461 |
| 2026-01-07 | Tatsis Ourania | -4,500 | $474.99 | $2,137,455 |
| 2026-01-06 | WAGNER CHARLES F JR | -9,532 | - | - |
| 2026-01-06 | WAGNER CHARLES F JR | -9,532 | $461 | $4,394,252 |
| 2026-01-06 | WAGNER CHARLES F JR | +9,532 | $189.38 | $1,805,170 |
| 2025-12-04 | LEIDEN JEFFREY M | -1 | - | - |
| 2025-12-04 | LEIDEN JEFFREY M | +1 | $91.05 | $91 |
| 2025-12-03 | Tatsis Ourania | -4,500 | $449.99 | $2,024,955 |
| 2025-12-03 | Biller Jonathan | -347 | $449 | $155,803 |
| 2025-12-03 | LEIDEN JEFFREY M | -63,781 | - | - |
| 2025-12-03 | LEIDEN JEFFREY M | -2,070 | $455.22 | $942,305 |
| 2025-12-03 | LEIDEN JEFFREY M | -10,360 | $453.34 | $4,696,602 |
| 2025-12-03 | LEIDEN JEFFREY M | -15,681 | $452.2 | $7,090,948 |
| 2025-12-03 | LEIDEN JEFFREY M | -5,809 | $451.2 | $2,621,021 |
| 2025-12-03 | LEIDEN JEFFREY M | -5,880 | $449.84 | $2,645,059 |
| 2025-12-03 | LEIDEN JEFFREY M | -2,320 | $448.78 | $1,041,170 |
| 2025-12-03 | LEIDEN JEFFREY M | -1,152 | $447.05 | $515,002 |
| 2025-12-03 | LEIDEN JEFFREY M | -7,899 | $445.56 | $3,519,478 |
| 2025-12-03 | LEIDEN JEFFREY M | -4,352 | $444.36 | $1,933,855 |
| 2025-12-03 | LEIDEN JEFFREY M | -2,469 | $443.21 | $1,094,285 |
| 2025-12-03 | LEIDEN JEFFREY M | -1,320 | $441.26 | $582,463 |
| 2025-12-03 | LEIDEN JEFFREY M | -4,469 | $440.4 | $1,968,148 |
| 2025-12-03 | LEIDEN JEFFREY M | +63,781 | $86.52 | $5,518,332 |
| 2025-12-03 | WAGNER CHARLES F JR | -7,000 | $461 | $3,227,000 |
| 2025-12-03 | WAGNER CHARLES F JR | -7,000 | $451 | $3,157,000 |
| 2025-11-19 | CARNEY LLOYD | -800 | - | - |
| 2025-11-17 | Atkinson Edward Morrow III | -2,500 | $434.58 | $1,086,450 |
| 2025-11-14 | LEIDEN JEFFREY M | -39,769 | - | - |
| 2025-11-14 | LEIDEN JEFFREY M | -13,835 | - | - |
| 2025-11-14 | LEIDEN JEFFREY M | -40 | $442 | $17,680 |
| 2025-11-14 | LEIDEN JEFFREY M | -21,330 | $441.35 | $9,413,996 |
| 2025-11-14 | LEIDEN JEFFREY M | -32,234 | $440.3 | $14,192,630 |
| 2025-11-14 | LEIDEN JEFFREY M | +39,769 | $86.52 | $3,440,814 |
| 2025-11-14 | LEIDEN JEFFREY M | +13,835 | $91.05 | $1,259,677 |
| 2025-11-13 | LEIDEN JEFFREY M | -19,688 | - | - |
| 2025-11-13 | LEIDEN JEFFREY M | -1,160 | $441.05 | $511,618 |
| 2025-11-13 | LEIDEN JEFFREY M | -18,528 | $440.22 | $8,156,396 |
| 2025-11-13 | LEIDEN JEFFREY M | +19,688 | $91.05 | $1,792,592 |
| 2025-10-15 | Upadhyay Suketu | +87 | $410.31 | $35,697 |
| 2025-10-15 | SACHS BRUCE I | +116 | $410.31 | $47,596 |